登录

Qitan Technology Snares ¥100M in Series A Round

作者: Mailman 2020-05-14 15:09

According to VCBeat, Qitan Technology, a start-up focusing on single-molecule nanopore DNA sequencing technology, has recently completed the Series A financing of more than 100 million yuan, with participation from Gaorong Capital, Yinxinggu Capital, and Alwin Capital. Proceeds from the latest round will be used for the research and development, production expansion, and marketing of products.


So far, Qitan Technology, founded in 2016, has completed four rounds of financing with a total of nearly 200 million yuan before the short-run trial production of products.


As the structure of the original nanopore-based sequencer has been confirmed, with protein and chips formed, the accuracy of one single sequencing up to 85% and the flux reaching 1G, Qitan Technology plans to launch the minimum viable product in 2020. Part of the proceeds will be used for the improvement of the product. The single-molecule sequencer, related reagents and consumables are expected to enter small-scale production in 2020, and gradually to market the final generation.


The project director of Gaorong Capital said the nanopore DNA sequencer Qitan Technology develops, is an interdisciplinary technical challenge, and it has made remarkable progress in protein engineering, fluid chips, electronic instrument, base recognition algorithm and so on, proved that the company has good strength in research and development. Gaorong Capital also looks forward to the application of nanopore extended in the genetic level to the transcriptome or even the proteome, to help the overall understanding of life.


>>>>

About Gaorong Capital


Gaorong Capital is devoted to creating a better life through innovation. It is dedicated to identifying the leading founders and collaborating with them to achieve long-term value. Gaorong Capital focuses on the investment of innovations in technology and business models along with industrial integration.


>>>>

About Yinxinggu Capital


Founded in 1997, Yinxinggu Capital is an investment platform that focuses on early investment opportunities in emerging industries, such as in retail and manufacturing, promoting the digital upgrade of the industry. The firm was jointly initiated by Slan Holdings, Huali Group, Huari Industrial, Jinggong Group, and Wanfeng Auto.

注:文中如果涉及企业数据,均由受访者向分析师提供并确认。
声明:动脉网所刊载内容之知识产权为动脉网及相关权利人专属所有或持有。转载请联系tg@vcbeat.net。

Mailman

医疗行业观察者

分享
动脉橙
以上数据来自动脉橙产业智库

我们以独创的在线数据库方式,为健康产业人士提供全方位和实时的市场资讯、行业数据和分析师见解。现已覆盖数字健康、医疗器械、生物医药等近500+细分赛道,涉及公司名单、招投标、投融资信息、头部企业动态等各类数据并持续更新。

点击 【申请试用】了解动脉橙产业智库更多内容。
精彩内容推荐

Biotechnology Company Matridx Completes ¥100M Pre-A Round of Financing

OBiO Closes on ¥100M Series B+ Funding Round

生物技术公司Emendo完成6100万美元B轮融资,开发下一代基因组编辑药物

China's Biotech Start-up Hui-Gene Therapeutics Raises $14M in Series A financing

Mailman

共发表文章3245篇

最近内容
  • 知之甚少:调研885名投资人后,原来美国VC们这样做决策

    2023-03-20

  • 辉瑞想要收购Seagen只是开始,这才是2023年并购的两大趋势

    2023-03-05

  • 【融资】核药企业Ratio再融资2000万美元,和拜耳合作研究新前列腺癌放射性疗法

    2023-02-09

上一篇

Elite Pharma Technology Closes ¥10M Series A Funding Round

2020-05-14
下一篇

中国肺癌罕见突变协作组正式成立,关注大癌种下的“罕见患者”

2020-05-14